Osteoradionecrosis Clinical Trial
Official title:
Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible, a Pilot Randomized Control Trial
Radiation is commonly used to treat cancer in the head and neck, however, this can lead to a serious complication called osteoradionecrosis (ORN), where there is necrotic (dead) open bone inside or outside of the mouth. This complication is difficult to treat, involves large healthcare costs, and can have devastating effects on quality of life. Two common adjuncts used in treatment of ORN are hyperbaric oxygen therapy (HBOT), which may requires up to 60 treatments at a specialized clinic where patients are treated with high concentrations of oxygen using special chambers, and a less complex option called PENTOCLO which involves treating patients with several antibiotics followed by a combination of other oral medications taken for at least 1 year. This pilot study will be guide the design of a definitive trial to examine if the combination of HBOT and a modified PENTOCLO protocol together is better than the current standard treatment of HBOT alone. Outcomes will include pain, side effects and the need for surgery in patients with ORN. Specifically, the results of this small, pilot study will help to inform the design of a future larger study.
Status | Not yet recruiting |
Enrollment | 24 |
Est. completion date | November 2025 |
Est. primary completion date | October 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Diagnosis of mandibular ORN after completion of radiotherapy - ORN will be defined as "an area of exposed devitalized irradiated bone (> 20 mm2)"; minor bone spicules (MBS) (< 20 mm2) in the absence of radiographic abnormality, will be considered clinically insignificant - Has no contraindications for undergoing hyperbaric oxygen therapy as assessed by a Hyperbaric Physician, and is willing to commit the time to undergo 60 sessions - Negative Human Chronic Gonadotropin (hCG) screening test at baseline (for female patients of reproductive age not practicing medically acceptable methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine device (IUD), intrauterine system (IUS), vasectomy and bilateral tubal ligation) - Baseline in-date ECG (within 60 days prior to enrolment) - Age = 18 Exclusion Criteria: - Inability to give informed consent - Previous treatment for ORN (PENTOCLO, HBOT or surgery) - Major surgical procedure planned (more extensive than sequestrectomy) - Severe trismus and inability to obtain intraoral photographs - Contraindications for HBOT: pneumothorax, bullous disease, uncontrolled hypertension, uncontrolled epilepsy, claustrophobia - Contraindications to mPENTOCLO: inability to swallow medication; pregnancy or lactating; allergy to any study drug; currently on oral anticoagulants; hemorrhagic/coagulation disorder; Vitamin K deficiency; active unresolved cardiac disease; severe liver or kidney disease (CrCl < 30 mL/min) - Known QT prolongation as documented on an in-date ECG (within 60 days prior to enrolment) - Currently on other drugs known to prolong the QT interval (e.g., erythromycin, cisapride, astemizole, pimozide or quinidine) - History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin-clavulanate - Moderate to severe liver disease (due potential for drug induced liver dysfunction) - History of myasthenia gravis - Patients with a history of nontraumatic tendon disorders or have experienced nontraumatic tendinitis or tendon rupture - Patients who have previously experienced peripheral neuropathy due to exposure to antibiotics - Smokers, high alcohol intake (average of >2 standard drinks per day), sepsis, severe undernourishment and severe immunodeficiency conditions (e.g. HIV, autoimmune disease, immune-compromised) - Persistent or recurrent cancer and active neoplastic pathology will be excluded - Patients with documented Vitamin K deficiency - Patients taking additional Vitamin E - Patients who have received previous anti-resorptive or anti-angiogenic medications - Patients diagnosed with retinitis pigmentosa - Patients diagnosed with clinically significant anemia |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sunnybrook Health Sciences Centre |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Quality of Life questionnaire | Assessed using EQ-5D-5L questionnaire | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Other | Xerostomia severity | Assessed using Xerostomia Inventory and/or Clinical Oral Dryness Score | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Other | Opioid usage | Medications and dosages (oral morphine equivalents) currently being taken by participants at each scheduled follow-up | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Other | ORN Pain | Assessed using Numerical Rating Scale (NRS) patient to rate their pain on scale of 0-10 where 0 is no pain and 10 is the worst pain imaginable | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Primary | Recruitment and adherence to protocol (process) | Recruitment of two subjects per month on average over 12 months | Pilot study (including 12-month follow-up) | |
Primary | Recruitment and adherence to protocol (process) | At least 70% of all eligible patients are recruited | Pilot study (including 12-month follow-up) | |
Primary | Recruitment and adherence to protocol (process) | More than 80% of all recruited subjects complete 60 sessions of HBOT (20/24) | Pilot study (including 12-month follow-up) | |
Primary | Recruitment and adherence to protocol (process) | More than 80% of patients in mPENTOCLO group complete mPENTOCLO protocol (10/12) | Pilot study (including 12-month follow-up) | |
Primary | Recruitment and adherence to protocol (process) | 80% 12-month follow-up rate (20/24) | Pilot study (including 12-month follow-up) | |
Primary | Feasibility (resource) - Time | Investigators to keep logs of time required to perform study related work | Pilot study (including 12-month follow-up) | |
Primary | Feasibility (resource) - Cost | Cost of study including research support and healthcare resource costs per patient | Pilot study (including 12-month follow-up) | |
Secondary | Recovery from ORN at one-year follow-up | Proportion of patients reaching recovery within the study period in each group. "Recovery" will be defined as the absence of pain, pathologic fracture, and cutaneous fistula; exposed bone area (EBA) less than 20 mm2; and by evidence of stabilization or regression on radiographic findings (Notani classification score). Minor bone spicules of less than 20 mm2 that have no ongoing pain, and no radiographic abnormalities will be considered fully healed and not Notani grade 1. | 12-month follow-up | |
Secondary | Time required to achieve recovery in patients | Difference in time required to reach recovery in each group. "Recovery" will be defined as the absence of pain, pathologic fracture, and cutaneous fistula; exposed bone area (EBA) less than 20 mm2; and by evidence of stabilization or regression on radiographic findings (Notani classification score). Minor bone spicules of less than 20 mm2 that have no ongoing pain, and no radiographic abnormalities will be considered fully healed and not Notani grade 1. | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Secondary | Improvement and failure rates in patients treated in each group using an accepted clinical and radiographic scoring system: | Exposed bone area (EBA) | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Secondary | Improvement and failure rates in patients treated in each group using an accepted clinical and radiographic scoring system: | Notani Classification Score
I ORN confined to dentoalveolar bone II ORN limited to dentoalveolar bone or mandible above the inferior dental canal, or both III ORN involving the mandible below the inferior dental canal, or pathological fracture, or skin fistula |
Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Secondary | Improvement and failure rates in patients treated in each group using an accepted clinical and radiographic scoring system: | Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) score | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) | |
Secondary | Complications that arise from treatment | Complications related to HBOT and/or mPENTOCLO, as defined in product monographs and study protocol. | Assessed at each scheduled follow-up (4 weeks, 5/6 weeks, and 3, 6, 9 and 12 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04265430 -
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
|
Phase 4 | |
Terminated |
NCT00989820 -
Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Osteoradionecrosis
|
Phase 2/Phase 3 | |
Completed |
NCT01147315 -
ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution
|
N/A | |
Recruiting |
NCT04934644 -
The Effect of Hyperbaric Oxygen Treatment in Patients With Osteoradionecrosis.
|
N/A | |
Active, not recruiting |
NCT04009161 -
Osteoradionecrosis Rate in Patients Undergoing Radiotherapy for Head and Neck Cancer Treatment.
|
||
Completed |
NCT06428994 -
Risk for Subsequent Osteoradionecrosis in A Transferred Fibula Flap in Head and Neck Cancer Patients Undergoing Segmental Mandibulectomy: a Cohort Study
|
||
Recruiting |
NCT02661139 -
Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction
|
||
Recruiting |
NCT00760682 -
Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study
|
Phase 2 | |
Recruiting |
NCT05412849 -
Radiation Field, Dose and Fractionation Related to Mandibular Complications
|
||
Completed |
NCT02368457 -
Management of Mandibular ORN: PENTO as Medical Treatment
|
Phase 4 | |
Active, not recruiting |
NCT02057510 -
Observational Study of Dental Outcomes in Head and Neck Cancer Patients
|
||
Active, not recruiting |
NCT05325970 -
Clinical Registry of Long-Term Dental Outcomes in Head and Neck Cancer Patients
|
||
Completed |
NCT04717765 -
Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention
|
N/A |